Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pharmacyclics LLC.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
≥ 18 years old
Refractory or relapsed indolent NHL. Eligible WHO histologies include follicular NHL (Grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and mucosa-associated lymphoid tissue (MALT) types
Failed ≥ 1 previous regimens, one of which must have contained rituximab as either a single agent or in combination with chemotherapy
ECOG performance status score either 0 or 1
Willing and able to provide written informed consent
You may not be if
Laboratory values of:
Platelet count \< 50,000/µL
AST or ALT \> 2 x the upper limit of normal (ULN)
Total bilirubin \> 2 x ULN
Creatinine \> 2.0 mg/dL
and
Greater than three prior regimens (where a regimen is defined as a treatment for NHL given after disease progression)
Uncontrolled hypertension
Known history of porphyria, G6PD deficiency, HIV
Clareo Health | Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
